valsartan has been researched along with Fibrosis in 73 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.74) | 18.2507 |
| 2000's | 16 (21.92) | 29.6817 |
| 2010's | 34 (46.58) | 24.3611 |
| 2020's | 21 (28.77) | 2.80 |
| Authors | Studies |
|---|---|
| Chai, HT; Chen, CH; Chen, YL; Chiang, JY; Sung, PH; Yang, CC; Yip, HK | 1 |
| Qi, M; Sun, R; Wang, W; Yi, G; Yu, J; Zhuang, C | 1 |
| Chen, S; Kang, L; Liu, Y; Si, J; Xu, B; Zhong, C | 1 |
| Chen, J; Chen, S; Li, G; Qin, S; Qin, Y; Wang, S | 1 |
| Abdullah, DM; Alsemeh, AE; Khamis, T | 1 |
| Asghari, AA; Hosseini, SJ; Mahmoudabady, M; Mousavi Emadi, Z; Salmani, H | 1 |
| Duan, X; He, Y; Wu, Q; Yan, F; Zhu, H | 1 |
| Handa, T; Ikushima, A; Inoue, Y; Ishii, A; Ishimura, T; Kato, Y; Minamino, N; Mori, KP; Mukoyama, M; Nishio, H; Ohno, S; Sugioka, S; Yamada, H; Yanagita, M; Yokoi, H | 1 |
| Choudhary, G; Clements, RT; Fernandez-Nicolas, A; Kue, NR; Mallem, K; Mancini, TJ; McCullough, DJ; Morrison, AR; Vang, A | 1 |
| Ding, Z; Li, Y; Liu, R; Wang, Q; Zang, Y; Zhang, G; Zhang, X | 1 |
| Gorshunova, NK; Savich, VV | 1 |
| Cao, S; Huang, X; Jiang, X; Kang, Y; Mei, Q; Qin, D; Wu, AG; Wu, J; Yang, J; Ye, Y; Zhang, C | 1 |
| Ge, Q; Hu, Z; Liu, C; Pan, C; Ren, X; Yu, YH; Zhao, L | 1 |
| Jin, Q; Li, X; Wang, L; Wang, Q; Zhang, Q; Zheng, Y; Zhu, Q | 1 |
| Ikeda, G; Mercola, M; Tada, Y; Vaskova, E; Wahlquist, C; Yang, PC | 1 |
| Cao, Y; Chen, A; Chen, M; Fan, Y; Guan, X; Li, J; Liu, Y; Yang, D | 1 |
| Chen, X; Chen, Y; Cheng, Y; Chu, J; Li, J; Liu, H; Liu, L; Long, L; Peng, J; Shen, A; Shen, Z; Wu, M; Xie, Q | 1 |
| Chandrabhatla, AS; Christiansen, SL; Holmes, JW; Nelson, AR; Saucerman, JJ; Zeigler, AC | 1 |
| Adams, V; Augstein, A; Barthel, P; Draskowski, R; Galli, R; Goto, K; Jannasch, A; Kirchhoff, V; Linke, A; Männel, A; Mittag, J; Schauer, A; Winzer, EB | 1 |
| Li, CY; Li, SN; Xi, H; Zhang, JR; Zhao, L; Zhou, L | 1 |
| Braza, J; Choudhary, G; Li, X; Mende, U; Zhang, P | 1 |
| Netticadan, T; Parikh, M; Raj, P; Sayfee, K; Wigle, J; Yu, L; Zieroth, S | 1 |
| Asada, N; Awazu, M; Furuhata, M; Hashiguchi, A; Matsuoka, D; Naganuma, K; Noda, S; Tsukahara, T | 1 |
| Chen, W; Dong, J; Gao, D; Guo, H; Lu, Y; Pan, X; Sun, Y; Xu, D; Xu, Y | 1 |
| An, S; Duan, L; Gao, Y; Liu, J; Liu, Y; Tian, L; Wang, J; Wang, S; Wei, S; Zhou, S | 1 |
| Jing, W; Kashyap, ML; Khazaeli, M; Moradi, H; Nunes, A; Suematsu, Y; Vaziri, ND | 1 |
| Akagi, S; Ito, H; Kondo, M; Miura, D; Miyoshi, T; Nakamura, K; Ohno, Y; Saito, Y; Yoshida, M | 1 |
| Gao, X; He, L; Sun, YH; Tian, HP; Xu, DL; Yi, YF | 1 |
| Ahmad, SNS; Argani, H; Ashrafi-Jigheh, Z; Asiaee, F; Aslani, S; Bahrambeigi, S; Ghorbani Haghjo, A; Rashedi, J; Rashtchizadeh, N; Roshangar, L; Sanajou, D | 1 |
| Aroor, AR; Chandrasekar, B; Das, NA; DeMarco, VG; Habibi, J; Hayden, MR; Johnson, MS; Manrique-Acevedo, CM; Nistala, R; Wiedmeyer, C | 1 |
| Burke, RM; Lighthouse, JK; Mickelsen, DM; Small, EM | 1 |
| Li, N; Ma, R; Yu, J; Yu, X; Zhao, X; Zhao, Y | 1 |
| Ahmed, R; Berk, BC; Doyley, MM; Faiyaz, A; Korshunov, VA; Quinn, B; Sowden, MP | 1 |
| Chen, CH; Chen, YL; Chen, YT; Huang, TH; Li, YC; Shao, PL; Sun, CK; Yang, CC; Yip, HK | 1 |
| Aimo, A; Emdin, M; Maisel, AS | 1 |
| Hatou, S; Imada, T; Ishida, S; Kawakami, Y; Kawakita, T; Miyashita, H; Mori, T; Nakamura, S; Ogawa, Y; Okamoto, S; Ozawa, Y; Satofuka, S; Shimmura, S; Tsubota, K; Yaguchi, S; Yaguchi, T; Yoshida, S | 1 |
| Bobkova, IN; Chebotareva, NV; Kozlovskaia, LV; Li, OA; Nanchikeeva, ML; Plieva, OK | 1 |
| Atar, D; Huang, L; Jordaan, P; Kompa, AR; Krum, H; von Lueder, TG; Wang, BH; Webb, R | 1 |
| Hasegawa, Y; Kim-Mitsuyama, S; Koibuchi, N; Kusaka, H; Lin, B; Nakagawa, T; Ogawa, H; Sueta, D | 1 |
| Sui, X; Wang, D; Wei, H | 1 |
| Bi, X; Li, S; Ma, X; Miao, Y; Su, G; Sun, H; Zhang, W; Zhang, Y; Zhao, Y; Zhong, M | 1 |
| Cheng, WP; Lo, HM; Shyu, KG; Wang, BW | 1 |
| Chen, JH; Chen, LL; Chen, XH; Fu, FY; Tang, MR; Wang, WW; Zhang, FL | 1 |
| Arimura, T; Goto, M; Imaizumi, S; Iwata, A; Kuwano, T; Matsuo, Y; Miura, S; Saku, K; Suematsu, Y; Yahiro, E | 1 |
| Baicu, CF; Claggett, BL; Jhund, PS; Lefkowitz, M; McMurray, JJ; Pieske, B; Prescott, MF; Shi, V; Solomon, SD; Voors, AA; Zile, MR | 1 |
| Sabbah, HN | 1 |
| Chen, X; Gao, X; Lu, G; Luo, C; Luo, J; Peng, L; Zuo, Z | 1 |
| Cheng, Q; de Gasparo, M; Law, PK; Leung, PS | 1 |
| Imaizumi, T; Kai, H; Kuwahara, F; Mizoguchi, M; Mizuta, Y; Nakaura, H; Osada, K; Tahara, N | 1 |
| Akashiba, A; Ishimitsu, T; Matsuoka, H; Ono, H; Ono, Y | 1 |
| Finckenberg, P; Kaheinen, P; Levijoki, J; Louhelainen, M; Merasto, S; Mervaala, E; Vahtola, E | 1 |
| Chen, JW; Fang, J; Gao, J; Huang, HQ; Liu, PQ; Tang, FT; Wang, P; Xu, SW; Zhou, SG | 1 |
| Chang, CH; Chiu, YT; Ku, CL; Shu, KH; Wen, MC; Wu, MJ; Wu, WP | 1 |
| Cheng, X; Lin, S; Wu, R; Zhou, Q | 1 |
| Bao, HG; Chen, YQ; Li, PH; Li, T; Ma, L; Wang, ZG; Zhang, WZ | 1 |
| Border, WA; Cheung, AK; Gu, C; Huang, Y; Noble, NA; Zhou, G | 1 |
| Ardhanari, S; DeMarco, VG; Ferrario, CM; Habibi, J; Hayden, MR; Krueger, C; Pulakat, L; Rehmer, N; Sowers, JR; Whaley-Connell, A | 1 |
| Bedigian, MP; Lu, L; Robinson, AD; Sun, Y; Weber, KT; Zhang, J | 1 |
| Khalil, N; Mancini, GB | 1 |
| Kawano, H; Koide, Y; Nakamizo, R; Seto, S; Toda, G; Yano, K | 1 |
| Chen, YP; Dong, HR; Qiu, CB; Zhang, C | 1 |
| Gong, HP; Li, L; Ma, X; Miao, Y; Sun, H; Zhang, W; Zhang, Y; Zhong, M | 1 |
| Chen, N; Hao, L; Sun, G; Wang, W; Wu, K; Zhang, Y; Zhou, T | 1 |
| Akdag, I; Filiz, G; Gullulu, M; Kahvecioglu, S; Savci, V | 1 |
| Chen, S; Huang, H; Li, R; Liu, P; Tang, F; Wang, P; Zhang, H | 1 |
| Fujita, T; Hishikawa, K; Imai, N; Marumo, T; Matsuzaki, Y; Okano, H; Shimosawa, T; Takase, O | 1 |
| Ikee, R; Kobayashi, S; Maesato, K; Mano, T; Moriya, H; Ohtake, T; Oka, M | 1 |
| Baicu, SC; Crawford, FA; de Gasparo, M; Hendrick, JW; King, MK; Loging, JA; New, RB; Spinale, FG | 1 |
| De Gasparo, M; Fornes, P; Gervais, M; Giudicelli, JF; Richer, C | 1 |
| Horikoshi, S; Kimura, M; Nakamura, S; Shirato, I; Suzuki, Y; Thang, NT; Tomino, Y | 1 |
| Lau, CP; Tipoe, GL; Wing-Hon Lai, K; Yu, CM | 1 |
| Cooper, ME; Cox, AJ; Gilbert, RE; Kelly, DJ; Tolcos, M; Wilkinson-Berka, JL | 1 |
1 review(s) available for valsartan and Fibrosis
| Article | Year |
|---|---|
Silent disease progression in clinically stable heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Apoptosis; Atrial Natriuretic Factor; Biphenyl Compounds; Calcium; Disease Progression; Diuretics; Drug Combinations; Fibrosis; Heart Failure; Humans; Mitochondria, Heart; Myocardium; Myocytes, Cardiac; Natriuretic Agents; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stress, Mechanical; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2017 |
3 trial(s) available for valsartan and Fibrosis
| Article | Year |
|---|---|
Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Blood Proteins; Double-Blind Method; Drug Combinations; Female; Fibrosis; Galectin 3; Galectins; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Male; Matrix Metalloproteinase 2; Middle Aged; Myocardium; Peptide Fragments; Procollagen; Prospective Studies; Receptors, Cell Surface; Severity of Illness Index; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2016 |
Long-term treatment with valsartan improved cyclic variation of the myocardial integral backscatter signal and diastolic dysfunction in hypertensive patients: the echocardiographic assessment.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Echocardiography; Female; Fibrosis; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardium; Prospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2008 |
Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Collagen Type I; Female; Fibrosis; Humans; Male; Middle Aged; Myocardium; Tetrazoles; Valine; Valsartan | 2005 |
69 other study(ies) available for valsartan and Fibrosis
| Article | Year |
|---|---|
Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat.
Topics: Aminobutyrates; Animals; Apoptosis; Biphenyl Compounds; Cardio-Renal Syndrome; Cardiovascular Agents; Drug Combinations; Fibrosis; Humans; Inflammation; Kidney; Male; Myocardium; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Simendan; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
Sacubitril/Valsartan Improves Sexual Function and Fibrosis of the Clitoral and Vaginal Tissues in Female Spontaneously Hypertensive Rats.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Female; Fibrosis; Hypertension; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Valsartan | 2022 |
The impact of Sacubitril/Valsartan on cardiac fibrosis early after myocardial infarction in hypertensive rats.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Drug Combinations; Fibrosis; Heart Failure; Hypertension; Myocardial Infarction; Rats; Rats, Inbred SHR; Tetrazoles; Valsartan | 2022 |
Effects of Valsartan on LN, FN, MDA, Renal Tissue Fibrosis, and Inflammatory Infiltration in DN Rats.
Topics: Animals; Diabetic Nephropathies; Fibronectins; Fibrosis; Laminin; Male; Rats; Valsartan | 2022 |
Sacubitril/valsartan (LCZ696) ameliorates hyperthyroid-induced cardiac hypertrophy in male rats through modulation of miR-377, let-7 b, autophagy, and fibrotic signaling pathways.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Autophagy; Biphenyl Compounds; Cardiomegaly; Drug Combinations; Epigenesis, Genetic; Fibrosis; Heart Failure; Hyperthyroidism; Male; MicroRNAs; Neprilysin; Rats; Rats, Wistar; Signal Transduction; Thyroxine; Valsartan | 2022 |
Sacubitril/Valsartan Improves Sexual Function and Fibrosis of the Clitoral and Vaginal Tissues in Female Spontaneously Hypertensive Rats: Erratum.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Female; Fibrosis; Heart Failure; Rats; Rats, Inbred SHR; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Cardiac hypertrophy and fibrosis were attenuated by olive leaf extract treatment in a rat model of diabetes.
Topics: Animals; Body Weight; Cardiomegaly; Diabetes Mellitus, Experimental; Fibrosis; Rats; Valsartan | 2022 |
Combination of tolvaptan and valsartan improves cardiac and renal functions in doxorubicin-induced heart failure in mice.
Topics: Animals; bcl-2-Associated X Protein; Caspase 3; Doxorubicin; Fibrosis; Heart Failure; Inflammation; Kidney; Kidney Diseases; Mice; Stroke Volume; Tolvaptan; Valsartan; Ventricular Function, Left | 2022 |
Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess.
Topics: Aldosterone; Animals; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibrosis; Kidney; Male; Mice; Natriuretic Peptides; Renal Plasma Flow; Valsartan | 2023 |
Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arterial Pressure; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Female; Fibrosis; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Neprilysin; Protease Inhibitors; Pulmonary Artery; Rats, Sprague-Dawley; Tetrazoles; Valsartan; Vascular Remodeling; Ventricular Dysfunction, Right; Ventricular Function, Right; Ventricular Remodeling | 2019 |
Silibinin Augments the Antifibrotic Effect of Valsartan Through Inactivation of TGF-β1 Signaling in Kidney.
Topics: Animals; Cell Line; Diabetic Nephropathies; Disease Models, Animal; Drug Synergism; Epithelial-Mesenchymal Transition; Fibrosis; Humans; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Renal Insufficiency, Chronic; Signal Transduction; Silybin; Transforming Growth Factor beta1; Valsartan | 2020 |
[Features of fibrosis and disorders of the collagen metabolism of the interstitial matrix of the myocardium in patients with arterial hypertension and possibilities of their correction with sartname.]
Topics: Aged; Case-Control Studies; Collagen; Female; Fibrosis; Heart; Humans; Hypertension; Myocardium; Spironolactone; Valsartan | 2019 |
Tandospirone enhances the anti-myocardial fibrosis effect of valsartan in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Cardiomyopathies; Drug Synergism; Fibrosis; Gene Expression; Hypertension; Immunohistochemistry; Isoindoles; Male; Models, Biological; Myocardium; Piperazines; Pyrimidines; Rats; Rats, Inbred SHR; Serotonin Receptor Agonists; Smad3 Protein; Transforming Growth Factor beta; Valsartan | 2020 |
LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Aortic Diseases; Biphenyl Compounds; Cardiomegaly; Constriction, Pathologic; Disease Models, Animal; Drug Combinations; Fibrosis; Male; Mice; Neprilysin; Receptors, Angiotensin; Tetrazoles; Valsartan | 2020 |
Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Fibrosis; Hypertrophy, Left Ventricular; Inflammasomes; Male; Mice, Inbred C57BL; Myocardium; Neprilysin; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Protease Inhibitors; Signal Transduction; Tetrazoles; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Sacubitril/Valsartan Improves Cardiac Function and Decreases Myocardial Fibrosis Via Downregulation of Exosomal miR-181a in a Rodent Chronic Myocardial Infarction Model.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cell Line; Down-Regulation; Drug Combinations; Exosomes; Female; Fibrosis; Humans; Induced Pluripotent Stem Cells; MicroRNAs; Myocardial Infarction; Myocytes, Cardiac; Neprilysin; Protease Inhibitors; Rats, Sprague-Dawley; Tetrazoles; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Drug Therapy, Combination; Fibrosis; Heart Failure; Hemodynamics; Inflammation Mediators; Male; Mice, Inbred C57BL; Myocardial Contraction; Myocardial Infarction; Myocardium; Neprilysin; Protease Inhibitors; Renin; Tetrazoles; Transforming Growth Factor beta1; Valsartan; Ventricular Function, Left | 2021 |
Qingda granule attenuates cardiac fibrosis via suppression of the TGF-β1/Smad2/3 signaling pathway in vitro and in vivo.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Echocardiography; Fibrosis; Male; Myocardium; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta1; Valsartan | 2021 |
Network model-based screen for FDA-approved drugs affecting cardiac fibrosis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Arsenic Trioxide; Biphenyl Compounds; Computer Simulation; Drug Combinations; Fibroblasts; Fibrosis; Heart Diseases; Humans; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Models, Animal; Network Pharmacology; Pyrazoles; Quaternary Ammonium Compounds; Quinolines; Rats; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad3 Protein; Thioctic Acid; Valsartan | 2021 |
Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Connectin; Cyclic GMP; Diastole; Disease Models, Animal; Drug Combinations; Electrocardiography; Female; Fibrosis; Glycated Hemoglobin; Heart Failure; Muscle, Skeletal; Muscular Atrophy; Natriuretic Peptide, Brain; Peptide Fragments; Phosphorylation; Rats, Mutant Strains; Valsartan; Ventricular Function, Left | 2021 |
Sacubitril/Valsartan Decreases Atrial Fibrillation Susceptibility by Inhibiting Angiotensin II-Induced Atrial Fibrosis Through p-Smad2/3, p-JNK, and p-p38 Signaling Pathways.
Topics: Aminobutyrates; Angiotensin II; Animals; Atrial Fibrillation; Biphenyl Compounds; Fibrosis; Rats; Signal Transduction; Valsartan | 2022 |
Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Aorta; Biphenyl Compounds; Cardiotonic Agents; Constriction; Disease Models, Animal; Drug Combinations; Early Medical Intervention; Fibroblasts; Fibrosis; Heart Ventricles; Male; Mitochondria, Heart; Myocytes, Cardiac; Oxidative Stress; Rats; Rats, Sprague-Dawley; RNA, Messenger; Superoxides; Valsartan; Ventricular Remodeling | 2021 |
Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Drug Combinations; Drug Interactions; Fibrosis; Humans; Male; Myocardial Infarction; Oxidative Stress; Rats; Rats, Sprague-Dawley; Resveratrol; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2021 |
Polycythemia, capillary rarefaction, and focal glomerulosclerosis in two adolescents born extremely low birth weight and premature.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Antigens, CD34; Apgar Score; Biopsy; Child; Endothelial Cells; Erythropoietin; Female; Fibrosis; Glomerulosclerosis, Focal Segmental; Hemoglobins; Humans; Infant, Extremely Premature; Infant, Newborn; Infant, Premature, Diseases; Infant, Very Low Birth Weight; Kidney Glomerulus; Kidney Tubules; Male; Microvascular Rarefaction; Nephrons; Platelet Endothelial Cell Adhesion Molecule-1; Polycythemia; Pregnancy; Premature Birth; Proteinuria; Valsartan | 2017 |
Valsartan attenuates pulmonary hypertension via suppression of mitogen activated protein kinase signaling and matrix metalloproteinase expression in rodents.
Topics: Animals; Blood Pressure; Cell Proliferation; Extracellular Matrix; Fibrosis; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; MAP Kinase Signaling System; Matrix Metalloproteinases; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Monocrotaline; Phosphorylation; Rats, Sprague-Dawley; Systole; Transforming Growth Factor beta1; Valsartan; Vascular Remodeling | 2017 |
Angiotensin II receptor blocker valsartan ameliorates cardiac fibrosis partly by inhibiting miR-21 expression in diabetic nephropathy mice.
Topics: Angiotensin Receptor Antagonists; Animals; Base Sequence; Biomarkers; Diabetic Nephropathies; Extracellular Matrix Proteins; Fibrosis; Gene Expression Regulation; Matrix Metalloproteinase 9; Mice, Inbred C57BL; MicroRNAs; Myocardium; Valsartan | 2018 |
LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiomegaly; Disease Models, Animal; Drug Combinations; Fibrosis; Heart Failure; Male; Neprilysin; Random Allocation; Rats; Rats, Sprague-Dawley; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Fibrosis; Hemodynamics; Humans; Hypertrophy, Left Ventricular; Isoproterenol; Myocardium; Neprilysin; Protease Inhibitors; Rats, Wistar; Tetrazoles; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Single-Stranded DNA-Binding Protein 1 Abrogates Cardiac Fibroblast Proliferation and Collagen Expression Induced by Angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Cell Proliferation; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type III; DNA-Binding Proteins; Fibrillar Collagens; Fibrosis; Heart; Male; Mice; Mice, Inbred C57BL; Mitochondrial Proteins; Myocardium; Myofibroblasts; Tumor Suppressor Protein p53; Valsartan; Vasoconstrictor Agents | 2018 |
Reduction of renal tubular injury with a RAGE inhibitor FPS-ZM1, valsartan and their combination in streptozotocin-induced diabetes in the rat.
Topics: Animals; Benzamides; Collagen; Diabetes Mellitus, Experimental; Drug Interactions; Epithelial Cells; Fibrosis; Glycation End Products, Advanced; Kidney Tubules; Male; Oxidative Stress; Rats; Rats, Wistar; Valsartan | 2019 |
The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Pressure; Biomarkers; Biphenyl Compounds; Blood Glucose; Diabetic Nephropathies; Disease Models, Animal; Drug Combinations; Fibrosis; Kidney Glomerulus; Kidney Tubules; Lipids; Male; Neprilysin; Nitrosative Stress; Oxidative Stress; Protease Inhibitors; Proteinuria; Rats, Zucker; Tetrazoles; Time Factors; Valsartan | 2019 |
Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cyclic GMP-Dependent Protein Kinases; Drug Combinations; Fibroblasts; Fibrosis; Heart; Heart Failure; Heart Ventricles; Male; Mice, Inbred C57BL; Neprilysin; Tetrazoles; Valsartan | 2019 |
AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Disease Models, Animal; Drug Combinations; Female; Fibrosis; Gene Expression Regulation; Hypertension; Hypertrophy, Left Ventricular; Myocytes, Cardiac; Neprilysin; Oxidative Stress; Protease Inhibitors; Rats, Inbred SHR; Rats, Inbred WKY; Renin-Angiotensin System; Signal Transduction; Tetrazoles; Valsartan; Vasodilation; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Strain-selective efficacy of sacubitril/valsartan on carotid fibrosis in response to injury in two inbred mouse strains.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Carotid Arteries; Carotid Artery Injuries; Drug Combinations; Fibrosis; Male; Mice, Inbred Strains; Species Specificity; Tetrazoles; Transcriptome; Valsartan; Vascular Stiffness | 2019 |
The therapeutic impact of entresto on protecting against cardiorenal syndrome-associated renal damage in rats on high protein diet.
Topics: Aminobutyrates; Animals; Apoptosis; Autophagy; Biomarkers; Biphenyl Compounds; Blood Urea Nitrogen; Cardio-Renal Syndrome; Creatinine; Diet, High-Protein; Drug Combinations; Fibrosis; Gene Expression Regulation; Kidney; Male; Mitochondria; Myocardium; NADPH Oxidases; Oxidative Stress; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptor, Angiotensin, Type 2; Tetrazoles; Valsartan | 2019 |
Sacubitril/Valsartan, Cardiac Fibrosis, and Remodeling in Heart Failure.
Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Extracellular Matrix; Fibrosis; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Angiotensin II type 1 receptor antagonist attenuates lacrimal gland, lung, and liver fibrosis in a murine model of chronic graft-versus-host disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Disease Models, Animal; Fibroblasts; Fibrosis; Gene Expression; Graft vs Host Disease; Histocompatibility Testing; Humans; Imidazoles; Lacrimal Apparatus; Liver; Lung; Male; Mice; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2013 |
[General molecular and cellular mechanisms for renal and cardiac remodeling in chronic kidney disease: a target for nephrocardioprotection].
Topics: Angiotensin II Type 1 Receptor Blockers; Biomarkers; Cardiotonic Agents; Fibrosis; Humans; Kidney; Myocardium; Myofibroblasts; Renal Insufficiency, Chronic; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2013 |
Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiomyopathy, Hypertrophic; Disease Models, Animal; Drug Combinations; Fibrosis; Male; Myocardial Infarction; Myocardium; Neprilysin; Rats; Rats, Sprague-Dawley; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2015 |
LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Cardiomegaly; Circadian Rhythm; Cyclic GMP; Drug Combinations; Drug Evaluation, Preclinical; Endothelium, Vascular; Fibrosis; Heart; Hypertension; Inflammation; Male; Myocardium; Neprilysin; Oxidative Stress; Random Allocation; Rats, Inbred SHR; Sodium, Dietary; Tetrazoles; Valsartan; Vascular Remodeling | 2015 |
Novel mechanism of cardiac protection by valsartan: synergetic roles of TGF-β1 and HIF-1α in Ang II-mediated fibrosis after myocardial infarction.
Topics: Angiotensin II; Animals; Blood Vessels; Cardiotonic Agents; Collagen; Fibrosis; Heart Function Tests; Hemodynamics; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocardial Infarction; Rats, Sprague-Dawley; Transforming Growth Factor beta1; Ultrasonography; Valsartan | 2015 |
Valsartan blocks thrombospondin/transforming growth factor/Smads to inhibit aortic remodeling in diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Aortic Diseases; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, High-Fat; Fibrosis; Male; Rats, Wistar; Signal Transduction; Smad Proteins; Smad2 Protein; Smad3 Protein; Streptozocin; Thrombospondin 1; Time Factors; Transforming Growth Factor beta1; Valsartan; Vascular Remodeling | 2015 |
MicroRNA-208a Increases Myocardial Endoglin Expression and Myocardial Fibrosis in Acute Myocardial Infarction.
Topics: Animals; Atorvastatin; Blotting, Western; Cells, Cultured; Disease Models, Animal; Endoglin; Fibrosis; Gene Expression Regulation; Hemodynamics; Heptanoic Acids; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Male; MicroRNAs; Muscle Cells; Myocardial Infarction; Polymerase Chain Reaction; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2015 |
Telmisartan reduces atrial arrhythmia susceptibility through the regulation of RAS-ERK and PI3K-Akt-eNOS pathways in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Apoptosis; Arrhythmias, Cardiac; Atrial Remodeling; Benzimidazoles; Benzoates; Blood Pressure; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Heart Rate; Hypertension; Male; Myocytes, Cardiac; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; ras Proteins; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; Telmisartan; Time Factors; Valsartan | 2015 |
LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Diabetes Mellitus, Experimental; Drug Combinations; Fibrosis; Heart; Heart Failure; Heart Ventricles; Male; Mice; Mice, Inbred C57BL; Myocardial Reperfusion Injury; Myocardium; Neprilysin; RNA, Messenger; Stroke Volume; Tetrazoles; Transforming Growth Factor beta; Valsartan | 2016 |
Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cells, Cultured; Disease Models, Animal; Diuretics; Fibroblasts; Fibrosis; Furosemide; Heart Failure; Heart Ventricles; Hydrochlorothiazide; Male; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Recovery of Function; Signal Transduction; Smad2 Protein; Stroke Volume; Transforming Growth Factor beta1; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2017 |
Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]
Topics: Adamantane; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Cell Proliferation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Drug Therapy, Combination; Fibrosis; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Mice; Pyrrolidines; Reactive Oxygen Species; Tetrazoles; Valine; Valsartan | 2008 |
Valsartan improves L-NAME-exacerbated cardiac fibrosis with TGF-ß inhibition and apoptosis induction in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Caspase 3; Fibrosis; Hypertension; Male; Myocardium; NG-Nitroarginine Methyl Ester; Rats; Rats, Inbred SHR; RNA; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan; Ventricular Remodeling | 2008 |
Effects of the calcium sensitizer OR-1896, a metabolite of levosimendan, on post-infarct heart failure and cardiac remodelling in diabetic Goto-Kakizaki rats.
Topics: Acetamides; Animals; Biomarkers; Cardiac Volume; Cellular Senescence; Diabetes Mellitus, Type 2; Fibrosis; Heart Failure; Inflammation; Mitochondria, Heart; Myocardial Infarction; Myocytes, Cardiac; Pyridazines; Random Allocation; Rats; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilator Agents; Ventricular Pressure | 2010 |
Tanshinone II-A attenuates cardiac fibrosis and modulates collagen metabolism in rats with renovascular hypertension.
Topics: Abietanes; Animals; Blood Pressure; Cardiovascular Agents; Collagen; Drugs, Chinese Herbal; Fibrosis; Gene Expression; Heart; Hypertension, Renovascular; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocardium; Phytotherapy; Rats; Rats, Sprague-Dawley; RNA, Messenger; Salvia miltiorrhiza; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Valine; Valsartan | 2010 |
A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren.
Topics: Actins; Amides; Anatomy, Cross-Sectional; Animals; Antihypertensive Agents; Blood Pressure; Blotting, Western; Collagen; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Fumarates; Immunohistochemistry; Kidney; Kidney Diseases; Kidney Function Tests; Male; Neutrophil Infiltration; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Snail Family Transcription Factors; Tetrazoles; Transcription Factors; Ureteral Obstruction; Valine; Valsartan | 2010 |
Fosinopril and valsartan intervention in gene expression of Klotho, MMP-9, TIMP-1, and PAI-1 in the kidney of spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Fibrosis; Fosinopril; Glucuronidase; Hypertension; Kidney; Klotho Proteins; Male; Matrix Metalloproteinase 9; Plasminogen Activator Inhibitor 1; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; RNA, Messenger; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Valine; Valsartan | 2010 |
[Effects of valsartan and U0126 on atrial fibrosis and connexin40 remodeling in rats].
Topics: Animals; Butadienes; Connexins; Fibrosis; Gap Junction alpha-5 Protein; Heart Atria; Male; Myocardium; Nitriles; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2011 |
Targeting reduction of proteinuria in glomerulonephritis: Maximizing the antifibrotic effect of valsartan by protecting podocytes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dose-Response Relationship, Drug; Fibrosis; Glomerulonephritis; Intracellular Signaling Peptides and Proteins; Kidney; Kidney Function Tests; Male; Membrane Proteins; Podocytes; Proteinuria; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2014 |
Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling.
Topics: Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cell Size; Drug Interactions; Fibrosis; Fumarates; Mice; Myocardium; Myocytes, Cardiac; Oxidative Stress; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptor, Angiotensin, Type 1; Renin; Signal Transduction; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2013 |
Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Collagen Type I; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Heart; In Situ Hybridization; Infusions, Parenteral; Male; Myocardium; Nephrectomy; NF-kappa B; Rats; Rats, Sprague-Dawley; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan | 2004 |
Angiotensin II type 1 receptor blocker inhibits pulmonary injury.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antimetabolites, Antineoplastic; Bleomycin; Blotting, Western; Collagen; Connective Tissue Growth Factor; Enzyme-Linked Immunosorbent Assay; Female; Fibrosis; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Lung; Macrophages; Rats; Rats, Sprague-Dawley; Tetrazoles; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan | 2005 |
[The therapeutic effects of bosentan and valsartan on renal interstitial fibrosis of chronic aristolochic acid nephropathy].
Topics: Animals; Aristolochic Acids; Bosentan; Collagen Type I; Connective Tissue Growth Factor; Disease Models, Animal; Fibrosis; Kidney; Kidney Diseases; Male; Plasminogen Activator Inhibitor 1; Rats; Rats, Sprague-Dawley; Sulfonamides; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1; Valine; Valsartan | 2005 |
[Mechanism of reversion of myocardial interstitial fibrosis in diabetic cardiomyopathy by valsartan].
Topics: Animals; Antihypertensive Agents; Blood Pressure; Blotting, Western; Cardiomyopathy, Hypertrophic; Diabetes Mellitus, Experimental; Fibrosis; Heart; Male; Myocardium; Random Allocation; Rats; Rats, Wistar; Receptors, Angiotensin; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tetrazoles; Thrombospondin 1; Transforming Growth Factor beta; Valine; Valsartan | 2006 |
Valsartan inhibited the accumulation of dendritic cells in rat fibrotic renal tissue.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Dendritic Cells; Disease Models, Animal; Disease Progression; Fibrosis; Immunohistochemistry; Kidney Diseases; Kidney Function Tests; Kidney Tubules; Membrane Glycoproteins; Proteinuria; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2006 |
Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cell Proliferation; Disease Models, Animal; Diuretics; Fibrosis; Glomerulonephritis, Membranoproliferative; Ki-67 Antigen; Kidney; Mineralocorticoid Receptor Antagonists; Rats; Rats, Sprague-Dawley; Spironolactone; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2006 |
Contribution of different Nox homologues to cardiac remodeling in two-kidney two-clip renovascular hypertensive rats: effect of valsartan.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Cardiomegaly; Disease Models, Animal; Fibrosis; Heart Ventricles; Hypertension, Renovascular; Ligation; Male; Malondialdehyde; Membrane Glycoproteins; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; NADPH Oxidase 2; NADPH Oxidase 4; NADPH Oxidases; Rats; Rats, Sprague-Dawley; Renal Artery; Superoxides; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2007 |
Angiotensin II type 1 receptor blockade prevents decrease in adult stem-like cells in kidney after ureteral obstruction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Female; Fibrosis; Flow Cytometry; Injections, Intraperitoneal; Kidney; Leukocyte Common Antigens; Mice; Mice, Inbred C57BL; Stem Cells; Tetrazoles; Ureteral Obstruction; Valine; Valsartan | 2007 |
Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biopsy; Creatinine; Female; Fibrosis; Glomerulonephritis, Membranoproliferative; Humans; Immunoglobulin A; Kidney Glomerulus; Losartan; Male; Middle Aged; Receptor, Angiotensin, Type 1; Retrospective Studies; Telmisartan; Tetrazoles; Valine; Valsartan; Vasodilation | 2008 |
Effects of angiotensin type-I receptor blockade on pericardial fibrosis.
Topics: Angiotensin Receptor Antagonists; Animals; Cardiac Surgical Procedures; Collagen; Fibrosis; Hydroxyproline; Male; Pericardium; Postoperative Complications; Receptors, Angiotensin; Reoperation; Swine; Tetrazoles; Valine; Valsartan | 1999 |
Valsartan and coronary haemodynamics in early post-myocardial infarction in rats.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Body Weight; Cardiomegaly; Coronary Vessels; Dipyridamole; Dose-Response Relationship, Drug; Fibrosis; Hemodynamics; Male; Myocardial Infarction; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 1999 |
Effect of valsartan, an angiotensin II AT(1) receptor blocker, on the glomerular fibrosis of IgA nephropathy in ddY mice.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Fibrosis; Glomerulonephritis, IGA; Kidney Glomerulus; Mice; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 2000 |
Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Collagen; Drug Combinations; Fibrosis; Fosinopril; Male; Myocardial Infarction; Myocardium; Random Allocation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan; Ventricular Remodeling | 2001 |
Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Apoptosis; Atrophy; Autoradiography; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epidermal Growth Factor; Female; Fibrosis; Gene Expression; In Situ Hybridization; In Situ Nick-End Labeling; Kidney Tubules; Nephritis, Interstitial; Perindopril; Rats; Renin-Angiotensin System; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2002 |